A phase Ila clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild -type p53 and MDM2 amplification or MDM2/CDK4 co-amplification

被引：0
|
作者：
Meric-Bernstam, F. [1 ]
Somaiah, N. [2 ]
DuBois, S. G. [3 ,4 ]
Dumbrava, E. E. Ileana [1 ]
Shapiro, G. I. [4 ]
Patel, M. R. [5 ]
Goel, S. [6 ]
Bauer, T. [7 ]
Pinchasik, D. [8 ]
Annis, A. [9 ]
Aivado, M. [10 ]
Vukovic, V. [11 ]
Saleh, M. [12 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Sarcoma Med Oncol, Houston, TX 77030 USA
[3] Dana Farber & Boston Childrens, Pediat Oncol, Boston, MA USA
[4] Dana Farber Canc Inst, Early Drug Dev Ctr, Boston, MA 02115 USA
[5] Florida Canc Specialists & Res Inst, Med Oncol, Sarasota, FL USA
[6] Montefiore Med Ctr, Med Oncol, Eastchester Albert Einstein Canc Ctr, East Campus,Med Pk, New York, NY USA
[7] Sarah Cannon Res Inst, Drug Dev, Nashville, TN USA
[8] Aileron Therapeut Inc, Clin Dev, Cambridge, MA USA
[9] Aileron Therapeut Inc, Res, Watertown, MA USA
[10] Aileron Therapeut Inc, Res & Drug Dev, Watertown, MA USA
[11] Aileron Therapeut Inc, Clin & Med, Watertown, MA USA
[12] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Hematol Oncol, Birmingham, AL USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
475P
引用
收藏
页码：179 / +
页数：2
相关论文
共 50 条
  • [31] BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53
    Luo, Yanwei
    Wang, Xinye
    Niu, Weihong
    Zhou, Yao
    Li, Mengna
    Ma, Jinqi
    Yang, Jing
    Fan, Songqing
    Zeng, Zhaoyang
    Xiong, Wei
    Li, Xiaoling
    Li, Guiyuan
    Xiao, Jidong
    Zhou, Ming
    JOURNAL OF CANCER, 2022, 13 (05): : 1436 - 1448
  • [32] AMG 232, a small molecular inhibitor of MDM2 augments radiation response in human tumors harboring wild-type p53
    Werner, Lauryn
    Huang, Shyhmin
    Armstrong, Eric A.
    Francis, Dave
    Osgood, Tao
    Canon, Jude
    Harari, Paul M.
    CANCER RESEARCH, 2014, 74 (19)
  • [33] First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
    Pairawan, Seyed
    Zhao, Ming
    Yuca, Erkan
    Annis, Allen
    Evans, Kurt
    Sutton, David
    Carvajal, Luis
    Ren, Jian-Guo
    Santiago, Solimar
    Guerlavais, Vincent
    Akcakanat, Argun
    Tapia, Coya
    Yang, Fei
    Bose, Priya Subash Chandra
    Zheng, Xiaofeng
    Dumbrava, Ecaterina Ileana
    Aivado, Manuel
    Meric-Bernstam, Funda
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [34] First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
    Seyed Pairawan
    Ming Zhao
    Erkan Yuca
    Allen Annis
    Kurt Evans
    David Sutton
    Luis Carvajal
    Jian-Guo Ren
    Solimar Santiago
    Vincent Guerlavais
    Argun Akcakanat
    Coya Tapia
    Fei Yang
    Priya Subash Chandra Bose
    Xiaofeng Zheng
    Ecaterina Ileana Dumbrava
    Manuel Aivado
    Funda Meric-Bernstam
    Breast Cancer Research, 23
  • [35] Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.
    Meric-Bernstam, Funda
    Saleh, Mansoor N.
    Infante, Jeffrey R.
    Goel, Sanjay
    Falchook, Gerald Steven
    Shapiro, Geoffrey
    Chung, Ki Y.
    Conry, Robert Martin
    Hong, David S.
    Wang, Judy Sing-Zan
    Steidl, Ulrich
    Walensky, Loren D.
    Guerlavais, Vincent
    Payton, Marie
    Annis, D. Allen
    Aivado, Manuel
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models
    Pairawan, S. S.
    Yuca, E.
    Evans, K.
    Annis, A.
    Narasimhan, N.
    Sutton, D.
    Carvajal, L. A.
    Ren, J-G
    Santiago, S.
    Guerlavais, V.
    Akcakanat, A.
    Tapia, C.
    Dumbrava, E. E. Illeana
    Aivado, M.
    Meric-Bernstam, F.
    CANCER RESEARCH, 2019, 79 (04)
  • [37] Intimal Sarcoma with MDM2/CDK4 Amplification and p16 Overexpression: A Review of Histological Features in Primary Tumor and Xenograft, with Immunophenotype and Molecular Profiling
    Giner, Francisco
    Machado, Isidro
    Rubio-Martinez, Luis Alberto
    Lopez-Guerrero, Jose Antonio
    Claramunt-Alonso, Reyes
    Navarro, Samuel
    Ferrandez, Antonio
    Mayordomo-Aranda, Empar
    Llombart-Bosch, Antonio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (08)
  • [38] Oral inflammatory myofibroblastic tumor demonstrating ALK, p53, MDM2, CDK4, pRb, and Ki-67 immunoreactivity in an elderly patient
    Brooks, JK
    Nikitakis, NG
    Frankel, BF
    Papadimitriou, JC
    Sauk, JJ
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2005, 99 (06): : 716 - 726
  • [39] Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
    W. Larry Gluck
    Mrinal M. Gounder
    Richard Frank
    Ferry Eskens
    Jean Yves Blay
    Philippe A. Cassier
    Jean-Charles Soria
    Sant Chawla
    Vincent de Weger
    Andrew J. Wagner
    David Siegel
    Filip De Vos
    Erik Rasmussen
    Haby A. Henary
    Investigational New Drugs, 2020, 38 : 831 - 843
  • [40] Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
    Gluck, W. Larry
    Gounder, Mrinal M.
    Frank, Richard
    Eskens, Ferry
    Blay, Jean Yves
    Cassier, Philippe A.
    Soria, Jean-Charles
    Chawla, Sant
    de Weger, Vincent
    Wagner, Andrew J.
    Siegel, David
    De Vos, Filip
    Rasmussen, Erik
    Henary, Haby A.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 831 - 843
12345